Dec 29, 2016
Medigen will conduct melanoma and esophageal cancer clinical trials with Oncolys
Medigen Corporation had signed with their alliance Oncolys on Dec. 26th 2016, to extend their co-develop oncolytic virus OBP-301 with new indication. To add on the clinical value of OBP-301, besides the advance stage liver cancer which is developing in Taiwan and Korea, melanoma and esophageal cancer will be added to be new indications. The permission of melanoma Phase II clerical trial was granted be FDA, and it will be carry out in the United States, while the esophageal cancer will be carry out in Japan.
Reference report:Report from Apple Daily (in Chinese)
Source： Medigen Biotechnology Corp.
http://www.medigen.com.tw/en/medigen-will-conduct-melanoma-and-esophageal-cancer-clinical-trials-with-oncolys/